Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Posted on by

The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology. COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.